Friday 6 November 2026 Export ELAN’s income statement to Excel — free account

Elanco Animal Health Incorporated

ELAN Healthcare Drug Manufacturers Specialty & Generic

Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.

Revenue: +10.2%
EPS: +450.0%
Free cash flow: +35.6%
Total debt: −6.91%

Quarter to June 2026, against a year earlier

23.74 1.57 −6.20%

Follow ELAN

Alert me

Market cap: $11.8B
P/E: 0.0×
Fwd P/E: 161×
Dividend yield: —
F-score: 5/9
Altman Z: 1.28
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Elanco Animal Health Incorporated (ELAN) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2019: revenue by products and services, and margins
Farm Animal:	1,855	60.40%
Pet Health	1,136	36.99%
Contract Manufacturing	80	2.61%
Gross margin		52.13%
Operating margin		6.02%
Pre-tax margin		2.54%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Pet Health	2,300 48.78%	2,143 48.28%	2,104 47.63%	2,138 48.47%	2,350 49.33%	1,356 41.46%	1,136 36.99%	—	—	—
Cattle	1,125 23.86%	1,007 22.69%	949 21.49%	944 21.40%	980 20.57%	—	—	—	—	—
Poultry	858 18.20%	796 17.93%	765 17.32%	716 16.23%	744 15.62%	—	—	—	—	—
Swine	379 8.04%	366 8.25%	382 8.65%	384 8.71%	464 9.74%	—	—	—	—	—
Contract Manufacturing	53 1.12%	46 1.04%	42 0.95%	54 1.22%	82 1.72%	80 2.45%	80 2.61%	94 3.06%	144 4.98%	90 3.07%
Aqua	0 0.00%	81 1.82%	175 3.96%	175 3.97%	144 3.02%	—	—	—	—	—
Farm Animal Ruminants And Swine	—	—	—	—	—	—	—	1,174 38.28%	1,175 40.67%	1,309 44.94%
Pet Health Disease Prevention	—	—	—	—	—	—	—	805 26.24%	660 22.85%	628 21.57%
Farm Animal Future Protein And Health	—	—	—	—	—	—	—	711 23.19%	649 22.47%	631 21.65%
Pet Health Therapeutics	—	—	—	—	—	—	—	283 9.23%	261 9.03%	256 8.77%
Farm Animal:	2,362	2,250	2,271	2,219	2,332	—	—	—	—	—
Revenue	4,715	4,439	4,417	4,411	4,764	3,271	3,071	3,067	2,889	2,914

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022
Reportable Segment	4,715 100.00%	4,439 100.00%	4,417 100.00%	4,411 100.00%
Revenue	4,715	4,439	4,417	4,411

Gross profit by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022
Reportable Segment	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
International	2,481 52.62%	2,403 54.13%	2,434 55.11%	2,446 55.45%	2,640 55.42%	1,796 54.91%	1,546 50.34%	1,584 51.64%	1,516 52.47%	1,552 53.27%
United States	2,234 47.38%	2,036 45.87%	1,983 44.89%	1,965 44.55%	2,124 44.58%	1,475 45.09%	1,525 49.66%	1,483 48.36%	1,373 47.53%	1,362 46.73%
Revenue	4,715	4,439	4,417	4,411	4,764	3,271	3,071	3,067	2,889	2,914

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Credelio Quattro penetration of U.S. clinic base	Q3 FY2026	55.0%	—	—
Farm animal price contribution	Q3 FY2026	3.00%	—	—
Pet health price contribution	Q3 FY2026	5.00%	9.00%	—
Pet health volume growth	Q3 FY2026	9.00%	9.00%	—

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025
Credelio Quattro penetration of U.S. clinic base	‡	‡	‡	‡	‡	‡	‡
Farm animal price contribution	‡	‡	‡	‡	‡	‡	‡
Pet health price contribution	‡	‡	‡	‡	‡	‡	‡
Pet health volume growth	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.